This site is intended for U.S. healthcare professionals.
Menu
Close
Menu
Close
Pivotal Trial Results
Post-Hoc Analysis Results
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Example of description text sitting alongside header
Example of description text sitting alongside header
Example of description text sitting alongside header
Example
See Starting & Monitoring information
Dosing
Dose Adjustments
Tab Number 3
Tab Number 4
Tab Number 5
Discontinue CIBINQO if an adequate response is not achieved with 200 mg.
Use the lowest effective dose to maintain response.
Dosing considerations
Dosing considerations
Limitations of Use: CIBINQO is not recommended for use in combination with other JAK inhibitors, biologic immuomodulators, or other immunosuppressants.
Swallow CIBINQO tablets whole with water. Do not crush, split, or chew CIBINQO tablets.
CIBINQO can be used with or without topical corticosteroids.
Take with or without food at approximately the same time each day. If patients experience nausea, it sometimes helps to take medicine with food.1-3
A 50 mg dose is available for special populations or modifications for certain adverse reactions.
– Patients with moderate renal impairment >
– Those on strong CYP2C19 inhibitors >
– CYP2C19 poor metabolizers >
Dosing recommendations are the same for pediatric patients (12 to <18 years) and for adults (≥18 years).
CIBINQO is contraindicated in patients taking antiplatelet therapies, except for low-dose aspirin (≤81 mg daily), during the first 3 months of treatment.
CIBINQO 50 mg once daily is the recommended dosage in patients who are known or suspected to be CYP2C19 poor metabolizers based on genotype or previous history/experience with other CYP2C19 substrates.§
Resources such as the discussion guide and patient brochure can help
A product representative is available to help you learn more about CIBINQO
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2024 Pfizer Inc. All rights reserved.